FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280497050> ?p ?o ?g. }

• W4280497050 endingPage "103632" @default.
• W4280497050 startingPage "103632" @default.
• W4280497050 abstract "Background: Ofatumumab, a fully human anti-CD20 monoclonal antibody, is approved for the treatment of relapsing multiple sclerosis (RMS) in adults. As per the ofatumumab label, females of childbearing potential should use effective contraception during and for at least 6 months after discontinuation of treatment. Data on the effect of ofatumumab on pregnancy outcomes are limited in humans. Based on the current knowledge, the maternal-fetal transfer of IgG during the first trimester is minimal and fetal IgG concentration starts to rise from the second trimester. Furthermore, in cynomolgus monkeys, exposure to ofatumumab during gestation did not cause maternal toxicity and there were no adverse effects on the pre- or postnatal development.Objective: To report pregnancy outcomes from the Novartis Safety Database in women with RMS inadvertently exposed to ofatumumab during pregnancy.Material(s) and Method(s): Pregnancy outcomes data from women with RMS exposed to ofatumumab during pregnancy or 6 months prior to last menstrual period were analyzed from clinical trials, and real-world setting in the Novartis Safety Database (cutoff: August 31, 2021). Maternal and infant outcomes including birth defects, congenital anomalies, infections, vaccination, and developmental delays were collected from the reporting of pregnancy up to 1 year of infant age.Result(s): As of cutoff date, 32 pregnancies with ofatumumab (ASCLEPIOS I/II, n=4; ALITHIOS, n=14; MIRROR, n=7; post-marketing, n=7) were reported in women with MS; of which 5 were ongoing and in 4 pregnancies, information on the outcomes was not reported. The remaining 23 pregnancies had the following outcomes: therapeutic/induced abortions (n=6), spontaneous abortion (n=5), early intrauterine fetal demise at ∼8.5 weeks gestation and patient underwent therapeutic abortion (n=1; not suspected to be related to ofatumumab by the treating physician), and 11 live births of normal babies. Based on followed-up data (up to 1 year of infant age), no B-cell depletion, immunoglobulin/hematological/fetal abnormalities, and serious infections were reported.Conclusion(s): In this analysis, no birth defects or congenital anomalies were reported in 23 pregnant women exposed to ofatumumab with known outcomes. There were no reports of B-cell depletion, immunoglobulin/hematological abnormalities, or serious infections in live births to date. Sharing the up-to-date data on pregnancy and infant outcomes with ofatumumab is helpful in counseling women with MS of childbearing potential. A prospective observational registry on maternal and infant outcomes in women exposed to ofatumumab is currently being planned. Background: Ofatumumab, a fully human anti-CD20 monoclonal antibody, is approved for the treatment of relapsing multiple sclerosis (RMS) in adults. As per the ofatumumab label, females of childbearing potential should use effective contraception during and for at least 6 months after discontinuation of treatment. Data on the effect of ofatumumab on pregnancy outcomes are limited in humans. Based on the current knowledge, the maternal-fetal transfer of IgG during the first trimester is minimal and fetal IgG concentration starts to rise from the second trimester. Furthermore, in cynomolgus monkeys, exposure to ofatumumab during gestation did not cause maternal toxicity and there were no adverse effects on the pre- or postnatal development. Objective: To report pregnancy outcomes from the Novartis Safety Database in women with RMS inadvertently exposed to ofatumumab during pregnancy. Material(s) and Method(s): Pregnancy outcomes data from women with RMS exposed to ofatumumab during pregnancy or 6 months prior to last menstrual period were analyzed from clinical trials, and real-world setting in the Novartis Safety Database (cutoff: August 31, 2021). Maternal and infant outcomes including birth defects, congenital anomalies, infections, vaccination, and developmental delays were collected from the reporting of pregnancy up to 1 year of infant age. Result(s): As of cutoff date, 32 pregnancies with ofatumumab (ASCLEPIOS I/II, n=4; ALITHIOS, n=14; MIRROR, n=7; post-marketing, n=7) were reported in women with MS; of which 5 were ongoing and in 4 pregnancies, information on the outcomes was not reported. The remaining 23 pregnancies had the following outcomes: therapeutic/induced abortions (n=6), spontaneous abortion (n=5), early intrauterine fetal demise at ∼8.5 weeks gestation and patient underwent therapeutic abortion (n=1; not suspected to be related to ofatumumab by the treating physician), and 11 live births of normal babies. Based on followed-up data (up to 1 year of infant age), no B-cell depletion, immunoglobulin/hematological/fetal abnormalities, and serious infections were reported. Conclusion(s): In this analysis, no birth defects or congenital anomalies were reported in 23 pregnant women exposed to ofatumumab with known outcomes. There were no reports of B-cell depletion, immunoglobulin/hematological abnormalities, or serious infections in live births to date. Sharing the up-to-date data on pregnancy and infant outcomes with ofatumumab is helpful in counseling women with MS of childbearing potential. A prospective observational registry on maternal and infant outcomes in women exposed to ofatumumab is currently being planned." @default.
• W4280497050 created "2022-05-22" @default.
• W4280497050 creator A5004420986 @default.
• W4280497050 creator A5008308300 @default.
• W4280497050 creator A5009564068 @default.
• W4280497050 creator A5015343257 @default.
• W4280497050 creator A5030373848 @default.
• W4280497050 creator A5033435187 @default.
• W4280497050 creator A5045567845 @default.
• W4280497050 creator A5051842646 @default.
• W4280497050 creator A5089098765 @default.
• W4280497050 date "2022-03-01" @default.
• W4280497050 modified "2023-09-28" @default.
• W4280497050 title "Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab" @default.
• W4280497050 doi "https://doi.org/10.1016/j.msard.2022.103632" @default.
• W4280497050 hasPublicationYear "2022" @default.
• W4280497050 type Work @default.
• W4280497050 citedByCount "3" @default.
• W4280497050 countsByYear W42804970502021 @default.
• W4280497050 countsByYear W42804970502023 @default.
• W4280497050 crossrefType "journal-article" @default.
• W4280497050 hasAuthorship W4280497050A5004420986 @default.
• W4280497050 hasAuthorship W4280497050A5008308300 @default.
• W4280497050 hasAuthorship W4280497050A5009564068 @default.
• W4280497050 hasAuthorship W4280497050A5015343257 @default.
• W4280497050 hasAuthorship W4280497050A5030373848 @default.
• W4280497050 hasAuthorship W4280497050A5033435187 @default.
• W4280497050 hasAuthorship W4280497050A5045567845 @default.
• W4280497050 hasAuthorship W4280497050A5051842646 @default.
• W4280497050 hasAuthorship W4280497050A5089098765 @default.
• W4280497050 hasBestOaLocation W42804970501 @default.
• W4280497050 hasConcept C126322002 @default.
• W4280497050 hasConcept C131872663 @default.
• W4280497050 hasConcept C159654299 @default.
• W4280497050 hasConcept C197934379 @default.
• W4280497050 hasConcept C203014093 @default.
• W4280497050 hasConcept C2778577042 @default.
• W4280497050 hasConcept C2778714382 @default.
• W4280497050 hasConcept C2778715236 @default.
• W4280497050 hasConcept C2779234561 @default.
• W4280497050 hasConcept C2780640218 @default.
• W4280497050 hasConcept C2780653079 @default.
• W4280497050 hasConcept C2781004633 @default.
• W4280497050 hasConcept C46973012 @default.
• W4280497050 hasConcept C54355233 @default.
• W4280497050 hasConcept C71924100 @default.
• W4280497050 hasConcept C86803240 @default.
• W4280497050 hasConceptScore W4280497050C126322002 @default.
• W4280497050 hasConceptScore W4280497050C131872663 @default.
• W4280497050 hasConceptScore W4280497050C159654299 @default.
• W4280497050 hasConceptScore W4280497050C197934379 @default.
• W4280497050 hasConceptScore W4280497050C203014093 @default.
• W4280497050 hasConceptScore W4280497050C2778577042 @default.
• W4280497050 hasConceptScore W4280497050C2778714382 @default.
• W4280497050 hasConceptScore W4280497050C2778715236 @default.
• W4280497050 hasConceptScore W4280497050C2779234561 @default.
• W4280497050 hasConceptScore W4280497050C2780640218 @default.
• W4280497050 hasConceptScore W4280497050C2780653079 @default.
• W4280497050 hasConceptScore W4280497050C2781004633 @default.
• W4280497050 hasConceptScore W4280497050C46973012 @default.
• W4280497050 hasConceptScore W4280497050C54355233 @default.
• W4280497050 hasConceptScore W4280497050C71924100 @default.
• W4280497050 hasConceptScore W4280497050C86803240 @default.
• W4280497050 hasLocation W42804970501 @default.
• W4280497050 hasOpenAccess W4280497050 @default.
• W4280497050 hasPrimaryLocation W42804970501 @default.
• W4280497050 hasRelatedWork W1965775453 @default.
• W4280497050 hasRelatedWork W2073757924 @default.
• W4280497050 hasRelatedWork W2085438061 @default.
• W4280497050 hasRelatedWork W2149819326 @default.
• W4280497050 hasRelatedWork W2192226300 @default.
• W4280497050 hasRelatedWork W2260535563 @default.
• W4280497050 hasRelatedWork W2732823864 @default.
• W4280497050 hasRelatedWork W2749256432 @default.
• W4280497050 hasRelatedWork W3114803364 @default.
• W4280497050 hasRelatedWork W4376871081 @default.
• W4280497050 hasVolume "59" @default.
• W4280497050 isParatext "false" @default.
• W4280497050 isRetracted "false" @default.
• W4280497050 workType "article" @default.